Markus Moehler

Markus Moehler at University Medical Center Mainz was the lead investigator of the CHECKMATE-649 trial establishing nivolumab plus chemotherapy as first-line standard of care for HER2-negative advanced gastric and GEJ cancer, a practice-changing result. His research on perioperative FLOT regimen in resectable gastric cancer and combined modality approaches has contributed to early-stage gastric cancer management. He has been a key European leader in gastric cancer clinical research and contributes to ESMO guidelines. His work bridges surgical, perioperative, and advanced disease management in gastric and GEJ cancers.